Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

Activity by year

2020202120222023202420252026

Expansion

Feb 11, 2020EXPANSIONNanjing, China; Chengdu, China, China
Meitheal Pharmaceuticals expands heparin manufacturing capacity in China
Meitheal Pharmaceuticals announced FDA approval of a new vial manufacturing line at NKF's Nanjing facility, doubling vial capacity to 100 million units. Plans include additional lines and a second Nanjing facility under construction, plus a new vial line in Chengdu.
Meitheal Pharmaceuticals Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. partner #Medical Devices pharmaceuticaldaily.com

Loading…